CompletedPhase 2NCT00431561
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Isarna Therapeutics GmbH
- Principal Investigator
- Ulrich Bogdahn, MD, MDUniversity of Regensburg, Dept. of Neurology, Germany
- Intervention
- AP 12009 10 µM(drug)
- Enrollment
- 141 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2003 – 2009
Study locations (30)
- Universitätsklinik Innsbruck; Abteilung für Neurochirurgie, Innsbruck, Austria
- Landes-Nervenklinik Wagner-Jauregg, Linz, Austria
- Kaiser Franz Josef Spital, Abteilung für Neurologie, Vienna, Austria
- Sarajishvili Institute of Clinical Neurology and Neurosurgery, Tbilisi, Georgia
- Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Berlin, Germany
- Klinik und Poliklinik für Neurologie, Cottbus, Germany
- Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany
- Universitätsklinikum Gießen, Neurochirurgische Universitätsklinik, Giessen, Germany
- Universitätsklinikum Kiel, Klinik für Neurochirurgie, Kiel, Germany
- Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie, Leipzig, Germany
- Universitätsklinik Magdeburg, Klinik für Neurochirurgie, Magdeburg, Germany
- Universitätskliniken Mainz, Neurochirurgische Klinik und Poliklinik, Mainz, Germany
- Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie, Münster, Germany
- Klinikum und Poliklinik für Neurologie, Universität Regensburg, Regensburg, Germany
- Klinikum Saarbrücken, Neurochirurgie, Saarbrücken, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00431561 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGPHASE1, PHASE2NCT07346144Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade GliomaTrogenix ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom